RETRACTED ARTICLE: Granisetron reduces the incidence and severity of nausea and vomiting after laparoscopic cholecystectomy

  • Yoshitaka Fujii
  • Hiroyoshi Tanaka
  • Hidenori Toyooka
Reports of Investigation

Abstract

Purpose

Postoperative nausea and vomiting (PONV) are commonly observed undesirable consequences of laparoscopic cholecystectomy. This study was undertaken to compare granisetron, a selective 5-hydroxytryptamine type 3 receptor antagonist, with dropendol for reducing the incidence and seventy of PONV after laparoscopic cholecystectomy.

Methods

Eighty patients, aged 25–65 yr. scheduled for elective laparoscopic cholecystectomy were enrolled in a randomized, double-blinded investigation and assigned to one of three treatment regimens: placebo (saline), 1.25 mg dropendol (approximately 25μg·kg−1) or 3 mg granisetron (approximately 60μg·kg−1). The study drugs were administerediv immediately before the induction of anaesthesia. A standard general anaesthetic technique was employed throughout. Nausea, vomiting and safety assessments were performed continuously dunng the first 24 hr after anaesthesia.

Results

The incidence of PONV was 46% with placebo, 41 % with dropendol and 15% with granisetron (P< 0.05; overall C2 test). Four patients who had received placebo and two who had received dropendol required another rescue antiemetic, compared with none who had received granisetron (P< 0.05). Adverse events postoperatively were not different among the groups.

Conclusion

Granisetron is more effective than dropendol and placebo for reducing the incidence and seventy of PONV after laparoscopic cholecystectomy.

Résumé

Objectif

Les nausées et vomissement postopératoires (NVPO) sont des complications fréquentes de la cholécystectomie par laparoscopie. Cette étude visait à comparer le granisetron. un antagoniste sélectif type de la 5-hydroxytriptamme. au dropéndol administré pour diminuer l’incidence et la gravité des NVPO après une cholécystectomie par laparoscopie.

Méthodes

Quatre-vingt patients, âgés de 25 à 65 ans, programmés pour une cholécystectomie par laparoscopie ont été recrutés pour cette étude aléatoire, en double aveugle et assignés à un des trois régimes suivants: placebo (sol phys.) dropéndol 1,25 mg(environ 25μg · kg−1) et granisetron 3 mg (environ 60μg· k−1). Les médicaments ont été administrésiv immédiatement avant l’induction de l’anesthésie. Une technique anesthésique standardisée était toujours utilisée Une évaluation des nausées, vomissements et des paramètres de sécurité était effectuée continuellement pendant 24 h après l’anesthésie.

Résultats

L’incidence des NVPO a été 46% avec le placebo, 41 % avec le dropéndol et 15% avec le granisetron (P< 0.05. test du C−1). Quatre des patients ayant reçu le placebo et deux le dropéndol ont eu besoin d’un antiémétique de sauvetage, comparativement à ceux qui avaient reçu le granisetron (P< 0.05). Les effets secondaires ont été les mêmes pour les trois groupes.

Conclusion

Administré pour diminuer l’incidence et la gravité des NVPO, le granisetron et plus efficace que le dropéndol et le placebo.

References

  1. 1.
    Stanton JM. Anaesthesia for laparoscopic cholecystectomy (Letter). Anaesthesia 1991; 46: 317.PubMedCrossRefGoogle Scholar
  2. 2.
    Iitomi T, Toriumi S, Kondo A, Akazawa T, Nakaham T. Incidence of nausea and vomiting after cholecystectomy performed via laparotomy or laparoscopy. (Japanese) Masui 1995; 44: 1627–31.PubMedGoogle Scholar
  3. 3.
    Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992; 77: 162–84.PubMedCrossRefGoogle Scholar
  4. 4.
    Naguib M, El Bakry AK, Khoshim MHB, et al. Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo. Can J Anaesth 1996; 43: 226–31.PubMedCrossRefGoogle Scholar
  5. 5.
    Andrews PLR, Bhandari P, Davey PT, Bingham S, Marr HE, Blower PR. Are all 5-HT3 receptor antagonists the same? Eur J Cancer 1992; 28A: S2–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Fujii Y, Tanaka H, Toyooka H. Reduction of postoperative nausea and vomiting with granisetron. Can J Anaesth 1994; 41: 291–1.PubMedCrossRefGoogle Scholar
  7. 7.
    Bermudez J, Boyle EA, Minter WD, Sanger GJ. The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer 1988; 58: 644–50.PubMedCrossRefGoogle Scholar
  8. 8.
    Carmichael J, Cantwell BMJ, Edwards CM, et al. A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response. Cancer Chemother Pharmacol 1989; 24: 45–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Furue H, Oota K, Taguchi T, Niitani H. Clinical evaluation of granisetron against nausea and vomiting induced by anticancer drugs. (I) Optimal dose-finding study. (Japanese) J Clin Ther Med 1990; 6 (Suppl 5): 49–61.Google Scholar
  10. 10.
    Fujii Y, Tanaka H, Toyooka H. Optimal anti-emetic dose of granisetron for preventing postoperative nausea and vomiting. Can J Anaesth 1994; 41: 794–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Korttila K, Kauste A, Auvinen J. Comparison of domperidone, droperidol, and metoclopramide in the prevention and treatment of nausea and vomiting after balanced general anesthesia. Anesth Analg 1979; 58: 396–400.PubMedCrossRefGoogle Scholar
  12. 12.
    Madej TH, Simpson KH. Comparison of the use of domperidone, droperidol and metoclopramide in the prevention of nausea and vomiting following gynaecological surgery in day cases. Br J Anaesth 1986; 58: 879–83.PubMedCrossRefGoogle Scholar

Copyright information

© Canadian Anesthesiologists 1997

Authors and Affiliations

  • Yoshitaka Fujii
    • 1
  • Hiroyoshi Tanaka
    • 1
  • Hidenori Toyooka
    • 1
    • 2
  1. 1.Department of AnacsthesiologyToride Kyodo General HospitalIbarakiJapan
  2. 2.Department of AnaesthesiologyUniversity of Tsukuba, Institute of Clinical MedicineIbarakiJapan

Personalised recommendations